Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Sponsor: Amgen
Summary
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
Official title: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-05-16
Completion Date
2031-04-23
Last Updated
2026-02-05
Healthy Volunteers
No
Conditions
Interventions
YL201
YL201 will be administered as an IV infusion.
Tarlatamab
Tarlatamab will be administered as an IV infusion.
Atezolizumab
Atezolizumab will be administered as an IV infusion.
Durvalumab
Durvalumab will be administered as an IV infusion.
Locations (36)
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, United States
Yale New Haven Hospital
New Haven, Connecticut, United States
Moffitt Cancer Center
Tampa, Florida, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Siteman Cancer Center
St Louis, Missouri, United States
Sanford Roger Maris Cancer Center
Fargo, North Dakota, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Sanford Oncology Clinic and Pharmacy
Sioux Falls, South Dakota, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Swedish Medical Center
Seattle, Washington, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
CHU de Quebec Hopital de l Enfant Jesus
Québec, Quebec, Canada
Shandong Cancer Hospital
Jinan, Shandong, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Fujian Cancer Hospital
Fuzhou, China
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
Gustave Roussy
Villejuif, France
Universitaetsklinikum Essen
Essen, Germany
Henry Dunant Hospital Center
Athens, Greece
Alexandra Hospital
Athens, Greece
European Interbalkan Medical Center
Thessaloniki, Greece
Iatriko Diavalkaniko Thessalonikis
Thessaloniki, Greece
Semmelweis Egyetem
Budapest, Hungary
Clinexpert Kft Bugat Pal Korhaz
Gyöngyös, Hungary
Istituto di Candiolo Fondazione del Piemonte per l Oncologia IRCCS
Candiolo to, Italy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola (FC), Italy
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy
Seoul National University Hospital
Seoul, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain